Exchange: NYSE·Updated 06:38 PM EDT
News
all
press releases
All You Need to Know About ADT (ADT) Rating Upgrade to Buy
ADT (ADT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Are Investors Undervaluing ADT (ADT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
ADT (ADT) Tops Q2 Earnings and Revenue Estimates
ADT (ADT) delivered earnings and revenue surprises of +4.55% and +1.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zacks Industry Outlook Highlights Allegion, MSA Safety, ADT and Alarm.com
Alarm.com is among security stocks positioned to benefit from strong demand for safety solutions despite industry cost and margin pressures.
Zacks
4 Security and Safety Stocks to Watch Despite Industry Headwinds
The prospects of the Zacks Security and Safety Services industry are hindered by increase in cost and growing labor expenses. ALLE, MSA, ADT and ALRM are some notable stocks in the industry.
Zacks
Should Value Investors Buy ADT (ADT) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Are Investors Undervaluing ADT (ADT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
J&J Phase 3 : Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes
(RTTNews) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT) given for six months before and after prostate cancer surgery. The investigational regimen s...
Nasdaq News: Markets
ADT (ADT) Upgraded to Buy: Here's Why
ADT (ADT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Is ADT (ADT) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks

Advertisement|Remove ads.